1. Hazen TC, Fliermans CB, Hirsch RP, Esch GW. Prevalence and distribution of Aeromonas hydrophila in the United States. Appl Environ Microbiol. 1978. 36:731–738.
2. Ko WC, Lee HC, Chuang YC, Liu CC, Wu JJ. Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteraemia. J Infect. 2000. 40:267–273.
3. Lay CJ, Zhuang HJ, Ho YH, Tsai YS, Wang LS, Tsai CC. Different clinical characteristics between polymicrobial and monomicrobial Aeromonas bacteremia: study of 216 cases. Intern Med. 2010. 49:2415–2421.
4. Kang JM, Kim BN, Choi SH, Kim NJ, Woo JH, Ryu J, Kim YS. Clinical features and prognostic factors of Aeromonas bacteremia. Infect Chemother. 2005. 37:161–166.
5. Sherlock CH, Burdge DR, Smith JA. Does Aeromonas hydrophila preferentially colonize the bowels of patients with hematologic malignancies? Diagn Microbiol Infect Dis. 1987. 7:63–68.
6. Krzymińska S, Kaznowski A, Lindner K, Mnichowska M. Enteropathogenic activity and invasion of HEp-2 cells by Aeromonas caviae clinical isolates. Acta Microbiol Pol. 2003. 52:277–283.
7. Laohachai KN, Bahadi R, Hardo MB, Hardo PG, Kourie JI. The role of bacterial and non-bacterial toxins in the induction of changes in membrane transport: implications for diarrhea. Toxicon. 2003. 42:687–707.
8. Janda JM. Biochemical and exoenzymatic properties of Aeromonas species. Diagn Microbiol Infect Dis. 1985. 3:223–232.
9. Dryden M, Munro R. Aeromonas septicemia: relationship of species and clinical features. Pathology. 1989. 21:111–114.
10. Motyl MR, McKinley G, Janda JM. In vitro susceptibilities of Aeromonas hydrophila, Aeromonas sobria, and Aeromonas caviae to 22 antimicrobial agents. Antimicrob Agents Chemother. 1985. 28:151–153.
11. Burgos A, Quindós G, Martínez R, Rojo P, Cisterna R. In vitro susceptibility of Aeromonas caviae, Aeromonas hydrophila and Aeromonas sobria to fifteen antibacterial agents. Eur J Clin Microbiol Infect Dis. 1990. 9:413–417.
12. Wu CJ, Wu JJ, Yan JJ, Lee HC, Lee NY, Chang CM, Shih HI, Wu HM, Wang LR, Ko WC. Clinical significance and distribution of putative virulence markers of 116 consecutive clinical Aeromonas isolates in southern Taiwan. J Infect. 2007. 54:151–158.
13. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. Document M45-A. 2006. Wayne, PA: Clinical and Laboratory Standards Institute.
14. Abbott SL, Cheung WK, Janda JM. The genus Aeromonas: biochemical characteristics, atypical reactions, and phenotypic identification schemes. J Clin Microbiol. 2003. 41:2348–2357.
15. Ormen O, Granum PE, Lassen J, Figueras MJ. Lack of agreement between biochemical and genetic identification of Aeromonas spp. APMIS. 2005. 113:203–207.
16. Lamy B, Laurent F, Verdier I, Decousser JW, Lecaillon E, Marchandin H, Roger F, Tigaud S, de Montclos H, Kodjo A. colBVH Study Group. Accuracy of 6 commercial systems for identifying clinical Aeromonas isolates. Diagn Microbiol Infect Dis. 2010. 67:9–14.
17. Duthie R, Ling TW, Cheng AF, French GL. Aeromonas septicaemia in Hong Kong species distribution and associated disease. J Infect. 1995. 30:241–244.
18. Janda JM, Guthertz LS, Kokka RP, Shimada T. Aeromonas species in septicemia: laboratory characteristics and clinical observations. Clin Infect Dis. 1994. 19:77–83.
19. Funada H, Matsuda T. Aeromonas bacteremia in patients with hematologic diseases. Intern Med. 1997. 36:171–174.
20. Harris RL, Fainstein V, Elting L, Hopfer RL, Bodey GP. Bacteremia caused by Aeromonas species in hospitalized cancer patients. Rev Infect Dis. 1985. 7:314–320.
21. Lee LN, Luh KT, Hsieh WC. Bacteremia due to Aeromonas hydrophila: a report of 40 episodes. Taiwan Yi Xue Hui Za Zhi. 1986. 85:123–132.
22. Ko WC, Chuang YC. Aeromonas bacteremia: review of 59 episodes. Clin Infect Dis. 1995. 20:1298–1304.
23. Lye DJ, Rodgers MR, Stelma G, Vesper SJ, Hayes SL. Characterization of Aeromonas virulence using an immunocompromised mouse model. Curr Microbiol. 2007. 54:195–198.
24. Yucel N, Erdogan S. Virulence properties and characterization of aeromonads isolated from foods of animal origin and environmental sources. J Food Prot. 2010. 73:855–860.
25. Galindo CL, Fadl AA, Sha J, Gutierrez C Jr, Popov VL, Boldogh I, Aggarwal BB, Chopra AK. Aeromonas hydrophila cytotoxic enterotoxin activates mitogen-activated protein kinases and induces apoptosis in murine macrophages and human intestinal epithelial cells. J Biol Chem. 2004. 279:37597–37612.
26. Garcia-Tsao G, Lee FY, Barden GE, Cartun R, West AB. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology. 1995. 108:1835–1841.
27. Quigley EM. Gastrointestinal dysfunction in liver disease and portal hypertension. Gut-liver interactions revisited. Dig Dis Sci. 1996. 41:557–561.
28. Such J, Guardiola JV, de Juan J, Casellas JA, Pascual S, Aparicio JR, Solá-Vera J, Pérez-Mateo M. Ultrastructural characteristics of distal duodenum mucosa in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2002. 14:371–376.
29. Chiva M, Guarner C, Peralta C, Llovet T, Gómez G, Soriano G, Balanzó J. Intestinal mucosal oxidative damage and bacterial translocation in cirrhotic rats. Eur J Gastroenterol Hepatol. 2003. 15:145–150.